These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34689317)

  • 1. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
    Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
    Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Na YM; Cho JS; Park MH
    Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of thyroid hormone supplementation after thyroid lobectomy.
    Lee DY; Seok J; Jeong WJ; Ahn SH
    J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
    Xiao L; Wu J; Jiang L; Xu Y; Liu B
    Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
    Dou Y; Chen Y; Hu D; Su X
    Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2015 American Thyroid Association guidelines and thyroid-stimulating hormone suppression after thyroid lobectomy.
    Reed R; Strumpf A; Martz TG; Kavanagh KJ; Fedder KL; Jameson MJ; Shonka DC
    Head Neck; 2021 Feb; 43(2):639-644. PubMed ID: 33124116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma.
    Ahn D; Lee GJ; Sohn JH; Jeon JH
    Head Neck; 2020 May; 42(5):1004-1013. PubMed ID: 31930773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up.
    Kim SY; Kim HJ; Kim SM; Chang H; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():520. PubMed ID: 32849303
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
    Zhang Q; Zhong ZZ; Wu T; He YQ
    BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
    Xia Q; Dong S; Bian PD; Wang J; Li CJ
    Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma.
    Park JH; Lee YM; Lee YH; Hong SJ; Yoon JH
    J Surg Oncol; 2018 Sep; 118(3):390-396. PubMed ID: 30114333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma.
    Lee SJ; Song CM; Ji YB; Choi YY; Sohn YS; Park JH; Kim DS; Tae K
    Langenbecks Arch Surg; 2021 Jun; 406(4):1223-1231. PubMed ID: 33970335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
    Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
    Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
    Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
    Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
    Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The magnitude of increased Levothyroxine dose during pregnancy in patients on thyroid-stimulating hormone (TSH) suppression treatment after total thyroidectomy for papillary carcinoma.
    Minakata M; Ito M; Kishi T; Hada M; Masaki Y; Nakamura T; Kousaka K; Kasahara T; Kudo T; Nishihara E; Fukata S; Nishikawa M; Akamizu T; Miyauchi A
    Endocr J; 2022 Feb; 69(2):165-172. PubMed ID: 34526424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
    Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?
    Cox C; Bosley M; Southerland LB; Ahmadi S; Perkins J; Roman S; Sosa JA; Carneiro-Pla D
    Surgery; 2018 Jan; 163(1):75-80. PubMed ID: 29122328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.